Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement

This prospective, single-center, single-arm, open-label pilot clinical study investigates the efficacy and safety of high-dose oral 35 kDa hyaluronan (HA35) for improving facial contour, reducing subcutaneous fullness, alleviating inflammatory erythema, enhancing facial vitality, and supporting body weight management.

Eligible subjects will take 5 g of oral HA35 once daily in the morning on an empty stomach for 40 consecutive days. Outcome assessments will be performed at baseline, Day 7, Day 14, Day 28, and Day 40 using a validated 0-10 Visual Analog Scale (VAS) to evaluate subcutaneous fat reduction, erythema improvement, facial vitality, and gastrointestinal tolerance. Body weight will be measured at each time point.

Safety evaluations include monitoring of adverse events, gastrointestinal comfort, dry eye symptoms, and overall tolerability.

This is a non-invasive, oral, non-pharmacological intervention with minimal risk to participants. All procedures will be conducted in accordance with the Declaration of Helsinki, and written informed consent will be obtained from all subjects prior to enrollment.

Inclusion criteria

• Age 18-60 years, male or female
• Seeking non-invasive improvement of facial/body appearance
• Presenting with facial fullness, double chin, subcutaneous fat accumulation, facial erythema, or dull skin
• Ability to complete VAS assessments and study logs
• Signed written informed consent

Exclusion criteria

• Aesthetic/weight loss treatments (injection, laser, liposuction, diet drugs) within 4 weeks
• Significant weight change (>3 kg) within 3 months
• Uncontrolled systemic disease (diabetes, hypertension, etc.)
• Known hypersensitivity to hyaluronan
• Pregnant or lactating women
• Participation in another clinical trial within 30 days